Company intelligence / Profile preview
Vivolux
Uppsala, Swedenvivolux.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Vivolux developed first-in-class small molecule drugs targeting hard-to-treat cancer cell populations. Their lead candidates, VLX600 and VLX1570, entered early clinical trials but both studies were terminated. VLX600 targeted metabolically compromised tumor cells in solid tumors; VLX1570 was a novel proteasome inhibitor for relapsed/refractory multiple myeloma. Both received FDA clearance for clinical testing and were studied at leading US cancer centers.
- Therapeutic areas
- Oncology
- Modalities
- Small moleculeIron chelatorProteasome inhibitor
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Mayo Clinic Cancer Center (clinical collaboration for VLX600)Memorial Sloan-Kettering Cancer Center and Dana-Farber Cancer Institute at Harvard Medical School (clinical collaboration for VLX1570)
Beyond the preview
Go deeper on Vivolux.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vivolux.